INTRODUCTION
Inherited fatty acid oxidation disorders (FOD) include defects of the cell membrane carnitine transporter, the "carnitine cycle" (CPT I, translocase, CPT II), or the mitochondrial I-oxidation spiral.
The most common disorders of I-oxidation affect very-long chain acyl-CoA dehydrogenase, mitochondrial trifunctional protein, isolated long-chain hydroxyacyl-CoA dehydrogenase, medium-chain-and short-chain acyl-CoA dehydrogenase. Patients with longchain FOD present commonly with recurrent hypoketotic hypoglycemia, hypertrophic or dilated cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, muscle weakness, and hypotonia, (for a review, see (21) ). There is considerable phenotypic variation associated with nearly all of these disorders.
The classical chronic treatment of long-chain FOD involves frequent feeding with a diet adjusted so as to lower long-chain fat intake from the usual 30-35% of total Kcal to about 20%, including essential fatty acids. The decrease in energy from long-chain fats is partly compensated by an increase in carbohydrates, often with cornstarch at bed time. In addition, even-carbon medium chain triglycerides (trioctanoin/tridecanoin) are added to the diet. This is because fatty acids with 8-10 carbons enter the mitochondrion as carboxylates which, after activation, require only those I-oxidative enzymes with medium-and short-chain length specificity. The dietary treatment with medium-chain triglycerides is obviously restricted to long-chain disorders and is contraindicated for medium-and short-chain deficiencies.
A new strategy was recently conceived for the dietary treatment of long-chain FOD, i.e., providing about one-third of the calories as triheptanoin (22) . The catabolism of heptanoate yields anaplerotic propionyl-CoA in addition to acetyl-CoA. It was hypothesized that part of the energy deficit in FOD patients results from a decrease in the concentration of citric acid cycle (16) . A 10% sterile emulsion of triheptanoin was kindly donated by Sasol Germany GmbH. As per Sasol's quality control data, the heptanoic acid used to synthesize triheptanoin contained 99.5% heptanoic acid, with traces of hexanoic, octanoic, and decanoic acids. The triheptanoin used to prepare the emulsion contained 97.5% triester, with the remaining 2.5% being monoester and diester. 
Animal experiments:
The animal experiments have been approved by the Institutional Animal Care and Utilization
Committee of the Case School of Medicine.
Preparation of rats: Male Sprague-Dawley rats were fed ad libitum with Harlan Teklad rat chow. After an overnight-fast, rats (235-317g) were anesthetized with intraperitoneal sodium pentobarbital (50 mg/kg dissolved in water). Catheters were inserted in a jugular vein and in the ventral tail artery. Some rats were also fitted with a catheter in the duodenum (through a small laparotomy). Following successful placement of catheters, saline (3.5 ml/hr) and a •kg -1 in the triheptanoin groups 2,3,4). In group 4, the tracers were infused intraduodenally with the triheptanoin emulsion. Arterial blood samples (70 µL) were taken at 0 (basal), 90, 100, 110, and 120 min. At 121 min, 0.5 ml of blood was again sampled from the abdominal aorta and the animals sacrificed as above. (16) . It also converts glucose to the M1 sorbitol.
After 30 min, protein denaturation was achieved with 50 µL of saturated sulfosalicylic acid. In those experiments measuring glucose and glycerol, samples were divided prior to the addition of sulfosalicylic acid and HCl by transferring 0.2 ml of solution to a separate tube. The glucose and glycerol tubes were then acidified with HCl, while sulfosalicyclic acid was added to the remaining tubes. Samples were stored at -20ºC until assayed.
Assay of heptanoate, C 4 -and C 5 -ketone bodies: After treatment with sulfosalicylic acid, the slurry was acidified with HCl and extracted with 3 x 4 ml of diethyl ether. The combined extract was dried over Na 2 SO 4 , evaporated down to about 50 µL, and sonicated for 1 hour with 3.5 µL pentafluorobenzyl bromide, 10 µL pyridine, and 37.5 µl acetonitrile. After extraction with 3 ml hexane, drying the extract over Na 2 SO 4 , and evaporating the solvent, the residue was reacted 
Data Analysis and Calculations:
Total C 4 ketone bodies were calculated as the sum of BHB and AcAc, while total C 5 ketone bodies were the sum of BHP and BKP. Glucose and glycerol R a were calculated (15) according to the steady-state equation:
where IE infusate is the isotopic enrichment of the tracer infusate, IE blood is the isotopic enrichment of blood, and INF is the rate of the tracer infusion (µmol•min ) determined by measurement of the total glycerol concentration in the triheptanoin emulsion after alkaline hydrolysis. Additional calculations were conducted to compute the isotopic data from experiments where triheptanoin was infused in the duodenum of rats (see text). All statistics (ANOVA with Tukey's post hoc analysis and t-tests) were performed using GB-Stat statistical software on a personal computer. Data are reported as means ± SEM. P # 0.05 was considered significant.
RESULTS
A major component of this study was the development of micro-analytical techniques so that all the assays required in the protocols could be conducted on 70 µL of whole blood.
Pentafluorobenzyl derivatives of carboxylic acids can be assayed using high-sensitivity ammonia negative chemical ionization mass spectrometry (11) . Immediate treatment of the samples with sodium borodeuteride allowed stabilization of unstable AcAc and BKP by conversion to stable monodeuterated BHB and BHP (4; 16) . These monodeuterated analytes were distinguished by mass spectrometric analysis from the corresponding undeuterated analytes. As a result of the use of sodium borodeuteride during sample processing, glucose was assayed as sorbitol. All the calibration curves were linear with substrate concentration
(not shown). The assays were conducted on whole blood because orientation experiments revealed that the concentration of heptanoate in whole blood was 48 to 74% of the concentration in plasma. This probably results from the partial equilibration of heptanoate concentration between plasma and erythrocytes.
In a first study (Protocol 1), we infused the triheptanoin emulsion for 90 min (i) at 0 to 40% of the caloric requirement intravenously, or (ii) at 40% of the caloric requirement intraduodenally. to 0.5 mM. In contrast, the intraduodenal infusion of triheptanoin at 40% of the caloric requirement resulted in a very low blood heptanoate concentration, i.e., about 0.02 mM. The blood heptanoate concentrations were undetectable (< 0.005 mM) in basal samples and in samples from saline-infused rats. Due to the small sample of blood that we were able to obtain from each rat, blood concentrations of triheptanoin were not obtained.
The blood concentration of C 5 -ketone bodies (BKP + BHP, Fig 2) was not detectable in basal samples or in the blood of saline-infused rats, but increased with the rate of intravenous triheptanoin infusion. However, the highest concentration of C 5 -ketone bodies was achieved during the intraduodenal infusion at 40% of the caloric requirement (about 0.22 mM; Fig 2, upper curve).
The basal blood concentrations of C 4 -ketone bodies (BHB + AcAc, Fig 3) ranged from 0.7 to 1.1 mM. As a result of the anesthesia, the concentration of physiological C 4 -ketone bodies increases from the usual concentration of about 0.1 mM in conscious overnight-fasted rats to about 1 mM (25). The high basal concentration of C 4 -ketone bodies continued to increase significantly in saline-infused rats (p < 0.05), again presumably as a result of the prolonged fasting and anesthesia, but decreased significantly during the intravenous infusion of triheptanoin at 30% and 40% of the caloric requirement (p < 0.001).
In the second study (Protocol 2), anesthetized rats were infused for 2 hr with either saline intravenously, triheptanoin at 40% of the caloric requirement intravenously, or triheptanoin at 40% of the caloric requirement intraduodenally. All rats were infused with [U- The blood glucose concentration (Fig 4A) was not significantly affected by the intravenous or intraduodenal infusion of triheptanoin except at 100 min, when glucose concentration was higher with intraduodenal triheptanoin infusion than with intravenous infusion (p < 0.05).
However, the rate of glucose appearance (glucose R a , Fig 4B) was significantly increased by about one half by the intraduodenal infusion of triheptanoin (p < 0.05).
The basal blood glycerol concentrations in all four groups were elevated (0.42 ± 0.06 mM),
compared to values from non-anesthetized animals (about 0.15 mM (20) ). This most likely results from the stress of the anesthesia and surgery, which stimulates lipolysis (5; 6). These effects are presumably mediated via increased concentrations of catecholamines and cortisol. Table 1 shows the detail of the calculations of the R a of glycerol in the four groups of rats of Protocol 2. In saline infused controls rats, the glycerol R a (21.7 µmol•min !1
•kg
) was similar to data from the literature (1) . The intravenous infusion of triheptanoin tripled the arterial blood glycerol concentration (Fig 4C) and about doubled the endogenous glycerol R a (Table 1, group 2), compared to the saline control. In contrast, the intraduodenal infusion of triheptanoin did not affect the arterial blood glycerol concentration (Fig 4C) . This suggests that, during the intraduodenal infusion of triheptanoin, the glycerol derived from the intestinal hydrolysis of triheptanoin was cleared by the liver. Therefore, to calculate the endogenous glycerol R a , one should not deduct from the total glycerol R a (endogenous + exogenous, 25.4 µmol•min •kg
is a reasonable first approximation of peripheral lipolysis during the intraduodenal infusion of triheptanoin. A small correction to this R a will be added below.
In the group of rats infused intraduodenally with triheptanoin and the glycerol tracer (Table 1, last row), the value of the total glycerol R a (endogenous + exogenous) calculated from the rate of tracer infusion and the enrichment of glycerol in arterial blood (238 µmol•min •kg
Second, in experiments with intraduodenal infusions of both triheptanoin and tracer glycerol (Table 1, •kg
To summarize the data of Table 1 , peripheral lipolysis (expressed as Glycerol R a ) was not substantially affected by the intraduodenal infusion of triheptanoin (groups 3 and 4), but was about doubled by the intravenous infusion of triheptanoin (group 2).
DISCUSSION
The initial clinical trial of FOD patients with triheptanoin involved mixing the triglyceride with baby formula or with semi-solid foodstuffs (22) . However, emulsions of triheptanoin might be used in the future for the treatment of patients with long-chain FOD, either enterally or intravenously for those who are going through acute decompensation. The latter patients are often comatose or confused, and require treatment via intravenous or/and naso-gastric administration. Temporary mal-absorption syndromes such as gastroenteritis in long-chain FOD patients could also necessitate the use of intravenous administration. This is why we conducted this study on anesthetized rats receiving triheptanoin either intravenously or intraduodenally. A constant level of anesthesia and adequate hydration were imposed by infusing a low dose of sodium pentobarbital dissolved in saline. The decrease in the concentration of C 4 -ketone bodies during the intravenous infusion of triheptanoin at 30% or 40% of the caloric requirement was quite puzzling, especially in view of the reported increase in C 4 -ketone bodies during infusion of even-chain triglycerides (mediumor long-chain) (3; 19; 23; 24) . Since the heptanoate molecule has two acetyl moieties, these were expected to contribute somewhat to the production of C 4 -ketone bodies. We considered the possibility that the intravenous infusion of triheptanoin could result in an inhibition of peripheral lipolysis, with a subsequent decrease in C 4 -ketogenesis. We thus decided to ) was only about one-third of the potential glucose equivalent of the triheptanoin infused (glycerol + propionyl-CoA moieties). This is because part of the propionyl-CoA moiety of heptanoate was converted to C 5 -ketone bodies (Fig 2) . During the intravenous infusion of triheptanoin, the glucose R a was not significantly increased ( Fig 4B) because a large fraction of the heptanoate derived from triheptanoin hydrolysis in blood was presumably taken up by non-gluconeogenic peripheral tissues. In contrast, during the intraduodenal infusion, all the glycerol and heptanoate derived from triheptanoin hydrolysis in the gut reached the liver, the main gluconeogenic organ.
The activation of lipolysis during the intravenous infusion of triheptanoin might result from the activation of lipoprotein lipase by the infused triglyceride. Karpe et al. showed that intravenous infusion of long-chain triglycerides in humans leads to an up to nine-fold activation of lipoprotein lipase in arterialized blood (14) . Nordenstrom et al. demonstrated a similar increase when a combination medium-chain/long-chain triglyceride infusion was infused, with greater lipoprotein lipase activities noted with the medium-chain/long-chain infusion than with long-chain infusion alone (18) . In this latter set of experiments there was a significant correlation (r=0.77) between plasma triglyceride concentrations and lipoprotein lipase activity during triglyceride infusion.
In our experiments where triheptanoin was infused intraduodenally (Table 1, groups 3, 4) , there was no increase in endogenous glycerol R a This is presumably because triglyceride particles did not enter the vascular bed and thus did not activate lipoprotein lipase.
During the intravenous infusion of triheptanoin, the activation of lipolysis presumably led to the release of long-chain fatty acids from adipose tissue. However, the arterial concentration of C 4 -ketone bodies decreased. This is an apparent contradiction since an increase in the supply of long-chain fatty acids to the liver would be expected to result in enhanced C 4 -ketogenesis. We suggest that the bulk of the long-chain fatty acids released by lipolysis was re-esterified while heptanoate was preferentially oxidized. Preferential oxidation of heptanoate would be favored because (i) it does not accumulate in adipose tissue (26) , and (ii) its oxidation bypasses the carnitine palmitoyltransferase system. Re-esterification of long-chain fatty acids occurs partly in the liver where the glycerol moiety of triheptanoin is activated to X-glycerophosphate, an intermediate of triglyceride synthesis. However, there are other sites of re-esterification (13) , in particular muscle which uses plasma glycerol for triglyceride synthesis (10) , and which is a site of triglyceride storage (8; 12) . Re-esterification of long-chain fatty acids in muscle was probably promoted by (i) the tripling in glycerol concentration during the intravenous infusion of triheptanoin (Fig 4C) , and (ii) the supply of energy substrates in the form of heptanoate and C 5 -ketone bodies. The increase in glucose R a and the slight hyperglycemia induced by triheptanoin infusion may have led to the release of insulin which promoted re-esterification of long-chain fatty acids in muscle and adipose tissue. Since fatty acids shorter than 9 carbons
are not stored as glycerides in the rat (26), the heptanoate moiety of triheptanoin was presumably oxidized in preference to the long-chain fatty acids released by enhanced lipolysis.
Experiments in dogs fitted with duodenal, trans-hepatic and trans-muscle catheters are planned to test the above mechanisms.
The data of this translational physiology study have a number of clinical implications for the potential use of triheptanoin emulsion in the treatment of long-chain FOD decompensation.
Currently, only the enteral form of triheptanoin is available for therapy, as part of semi-solid meals or baby formula. However, parenteral triheptanoin has the potential to be used during an acute decompensation or during episodes of malabsorption. The production of propionyl-
CoA from heptanoate or/and C 5 -ketone bodies would replenish the pool of Citric acid cycle intermediates and restore energy production. Since the heart is the organ with the highest activity of 3-oxoacid-CoA transferase (7) , it forms propionyl-CoA from both heptanoate and C 5 -ketone bodies.
The data of Figs 1 and 2 show that the intravenous and intraduodenal infusions of triheptanoin lead to opposite blood concentration ratios of (heptanoate)/(C 5 -ketone bodies). In some clinical conditions, one might prefer to administer triheptanoin intraduodenally to favor supplying C 5 -ketone bodies over heptanoate to peripheral tissues. It is likely that C 5 -ketone bodies, like C 4 -ketone bodies, can be taken up and used by the brain 1 which has very high activities of 3-oxoacid-CoA transferase and I-hydroxybutyrate dehydrogenase (7) . The intravenous administration of triheptanoin leads to an activation of lipolysis which would not be desirable during the acute treatment of long-chain FOD decompensation. However, this stimulation of lipolysis could then be countered by the re-esterification of long-chain fatty acids.
Re-esterification would be enhanced by the infusions of glucose and insulin which are used in severe cases of FOD decompensation. So, the addition of parenteral triheptanoin to the current treatment by glucose and insulin may be beneficial to these patients. In mild cases of FOD decompensation, enteral administration of triheptanoin emulsion would be preferred, in the absence of diarrhea.
We want to stress that we do not imply that this study, conducted in anesthetized rats, clears the way for the utilization of triheptanoin emulsion for the treatment of decompensated patients with long-chain FOD. This will require additional studies in larger animals with metabolic rates Table 1 Calculations of Glycerol R a in Protocol 2
Triheptanoin was infused at 40% of caloric requirement either intravenously (IV) or intraduodenally (ID). All rates are expressed in µmol·min The glucose R a data are shown only for groups 1-3 (intravenous infusion of labeled glucose).
